TMCnet News
Biophan Technologies Launches ''Biophan 101'' Corporate Video Presentation ROCHESTER, N.Y. --(Business Wire)-- Oct. 8, 2004 -- First in a Series of Productions Providing Layman's Introduction to Company's Growing Intellectual Property PortfolioBiophan Technologies, Inc. (OTC BB:BIPH), a developer of next-generation biomedical technology, has released the first in a series of short videos introducing and describing the patents and technologies that make up its rich intellectual property portfolio, the Company announced today. The video is designed to "deconstruct" the complexity of Biophan's cutting edge technologies and provide explanations that can be easily understood by the layperson. Interested investors can view the video online, via streaming video, at their convenience, at www.trilogy-capital.com. "We're calling this exciting and understandable explanation of our technology "Biophan 101" said Michael Weiner, CEO of Biophan. "It's targeted at the informed investor who may not be an engineer or scientist, but who wishes to learn more about Biophan's advanced biomedical technologies. Given the fast pace at which Biophan's intellectual property portfolio continues to grow, we want to educate our investors and potential investors about the new biomedical technology we're developing for the medical device marketplace. This professionally produced video provides a clear introduction to our technologies and their potential for improving health care for people around the world." Biophan recently announced that its portfolio of technologies has grown to a total of 92 patents, exclusive licenses, and patent applications. The video focuses on several of the technology families in this still-growing technology portfolio, which represents an unusually rich collection of intellectual property in the fields of nanotechnology for biomedical engineering, enhancement of Magnetic Resonance Imaging, implantable biothermal batteries, and other areas. About Biophan Technologies Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
